PEOPLE ON THE MOVE
Matinas BioPharma
New Jersey company Marinas BioPharma, which makes anti-fungal and anti-bacterial drugs, has made Raphael Mannino senior vice president and chief technology officer.
Mannino is an expert in the use of artificial lipid-based structures for drug formulation, and has pioneered the use of cochleate technology in this area. He helped invent Matinas BioPharma’s disruptive lipid-crystal nano-particle cochleate technology which encapsulate drugs to make them less toxic and improve bioavailability.
Mannino has been on the company’s scientific advisory board since the beginning of the year, and until recently worked as associate professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School.
"We have been working very closely with Dr Mannino as a scientific advisor and we are honored to officially welcome him as a member of our management team," said Roelof Rongen, CEO.
"Dr Mannino's research efforts and scientific contributions throughout the last 20 years have resulted in the cochleate delivery methods that are the cornerstone of our novel antifungal and anti-infective drug candidate programs which are progressing in collaboration with the National Institutes of Health.
“We look forward to advancing our clinical program for the lead drug candidate MAT2203, and our development program for MAT2501 under the guidance of one of the leading experts in the field."
